



INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2015 AND 2014
(UNAUDITED)
(EXPRESSED IN U.S. DOLLARS)

LED MEDICAL DIAGNOSTICS INC.

Interim Condensed Consolidated Statements of Financial Position (unaudited)

(Expressed in U.S. Dollars)

	Notes	March 31, 2015 (restated – note 8)	December 31, 2014
Assets			
Current assets			
Cash		\$ 1,109,109	\$ 2,396,994
Trade and other receivables		766,249	1,373,693
Inventory		1,842,742	3,103,636
Prepaid expenses and deposits		605,405	176,857
Total current assets		4,323,505	7,051,180
Non-current assets			
Prepaid expenses and deposits		286,600	287,500
Property and equipment		410,874	411,923
Patents and intellectual property		30,105	36,557
		\$ 5,051,084	\$ 7,787,160
Liabilities and Shareholders' Equity (Deficiency)			
Current liabilities			
Trade payables and accrued liabilities		\$ 1,675,867	\$ 4,301,950
Deferred revenue		251,599	1,124,621
Warrants		102,003	162,872
Current portion of finance lease obligation		2,138	3,190
Total current liabilities		2,031,607	5,592,633
Non-current liabilities			
Lease liability		61,279	24,512
Total liabilities		2,092,886	5,617,145
Shareholders' Equity (Deficiency)			
Share capital	4	34,845,480	34,145,786
Stock-based payment reserve	5	1,767,230	1,568,645
Warrants reserve		6,098,157	4,718,328
Accumulated other comprehensive income		474,458	474,458
Accumulated deficit		(40,227,127)	(38,737,202)
		2,958,198	2,170,015
<i>Nature and Continuation of Operations (Note 1)</i>		\$ 5,051,084	\$ 7,787,160

The accompanying notes are an integral part of these condensed consolidated financial statements

Approved on behalf of the Board:

signed "Dr. David Gane" Chief Executive Officer
Dr. David Gane

signed "Roger Tourigny" Director
Rodger Tourigny



LED MEDICAL DIAGNOSTICS INC.

Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(Expressed in U.S. Dollars)

For the three months ended March 31, 2015 and 2014

	Notes	March 31, 2015	March 31, 2014
(restated – note 8)			
Revenues		\$ 2,442,671	\$ 1,054,886
Cost of goods sold		1,814,119	525,537
		628,552	529,349
Expenses			
Sales and marketing		1,351,782	743,441
Research and development		50,102	258,581
Administration		666,780	532,690
Stock-based compensation	5	54,407	191,498
Other operating expenses		89,147	9,928
		2,212,218	1,736,138
Operating loss		(1,583,666)	(1,206,789)
Other expenses			
Mark to market adjustments on Canadian dollar denominated warrants		(60,870)	1,695,119
Foreign exchange loss (gain)		(32,872)	(7,909)
		(93,742)	(1,687,210)
Net loss and comprehensive loss before income taxes		(1,489,924)	(2,893,999)
Income taxes		-	-
Net loss and comprehensive loss for the period		\$ (1,489,924)	\$ (2,893,999)
Loss per share – basic and diluted		\$ (0.02)	\$ (0.04)
Weighted average number of shares outstanding – basic and diluted		92,659,700	73,574,248

The accompanying notes are an integral part of these condensed consolidated financial statements